Ontario Teachers Pension Plan Board Purchases 11,722 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Ontario Teachers Pension Plan Board boosted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 32.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,545 shares of the biotechnology company's stock after acquiring an additional 11,722 shares during the period. Ontario Teachers Pension Plan Board's holdings in Exelixis were worth $1,583,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in EXEL. MassMutual Private Wealth & Trust FSB raised its stake in Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock worth $63,000 after buying an additional 290 shares during the period. Steward Partners Investment Advisory LLC grew its stake in Exelixis by 4.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock valued at $235,000 after purchasing an additional 330 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after purchasing an additional 354 shares during the last quarter. Principal Securities Inc. raised its stake in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 373 shares in the last quarter. Finally, V Square Quantitative Management LLC boosted its holdings in shares of Exelixis by 37.3% in the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock valued at $52,000 after buying an additional 425 shares during the last quarter. Institutional investors own 85.27% of the company's stock.

Insiders Place Their Bets

In related news, Director Bob Oliver sold 18,647 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the transaction, the director now owns 33,514 shares in the company, valued at $1,248,396.50. The trade was a 35.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now owns 303,310 shares of the company's stock, valued at $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,343 shares of company stock worth $5,177,234. Company insiders own 2.85% of the company's stock.

Exelixis Price Performance

NASDAQ EXEL traded down $0.05 during trading hours on Monday, reaching $36.14. The company's stock had a trading volume of 349,891 shares, compared to its average volume of 2,168,261. The firm has a fifty day simple moving average of $36.44 and a 200-day simple moving average of $34.36. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The stock has a market cap of $10.12 billion, a P/E ratio of 20.42, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EXEL has been the topic of a number of recent analyst reports. Guggenheim restated a "buy" rating and set a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Piper Sandler raised their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. JMP Securities reiterated a "market outperform" rating and set a $41.00 price target on shares of Exelixis in a report on Thursday. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a research note on Thursday. Finally, Morgan Stanley upgraded Exelixis from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. Two analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.